Home › Bacterial Vaginosis › NCT05753813

Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome

Who can join

Ages 18 to 54 · Women · Healthy volunteers welcome

Inclusion Criteria:

* Age 18-54
* Female
* Pre-menopausal
* Can speak and read in English
* Displays capacity for informed consent
* Has had 2 or more documented and/or self-reported episodes of symptomatic BV or candida infection in the last year, requiring, over-the-counter or prescription treatment

Exclusion Criteria:

* Pregnant or trying to become pregnant
* Post-menopausal
* Using NuvaRing device
* A past medical history of kidney disease, recurrent UTI, and/or urinary tract abnormalities
* Current UTI
* Using Phexxi as a contraceptive during the collection period of the study

About the study

This project aims to investigate if the contraceptive method, Phexxi, causes changes to the composition of the vaginal microbiome. The investigators hypothesize that regular use of Phexxi will cause increased colonization of lactic acid-producing lactobacilli, which could have positive effects in the way of preventing recurrent episodes of BV and candida infections.

What is being tested

• Phexxi (drug)

Sponsor: Queen's Medical Center · Participants: 22 · Started: Dec 15, 2023

Contact the study team

• Olivia H Manayan, MD, MPH · Phone: 808-348-7859

Official record on ClinicalTrials.gov — NCT05753813

Locations in the U.S.

Conditions

• Bacterial Vaginosis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.